Menu

Jennifer Lawrence to Star in Theranos Movie

The actress will portray the troubled blood testing startup’s founder, Elizabeth Holmes. 

Jun 13, 2016
Tanya Lewis

Jennifer Lawrence at the April 16 premiere of “A Beautiful Planet” in New YorkNASA/JOEL KOWSKY

Actress Jennifer Lawrence is set to star as Elizabeth Holmes in a film about Theranos, the biotech startup that was valued at $9 billion before a Wall Street Journal investigation uncovered serious issues with some of the company’s claims, Deadline Hollywood reported last week (June 9). The film will be produced by Adam McKay, who recently produced The Big Short, the financial drama based on the book by Michael Lewis.

Meanwhile, Theranos’s troubles continue. Walgreens, the startup’s largest customer, yesterday (June 12) announced that it is ending its partnership with the firm. “In light of the voiding of a number of test results, and as the Centers for Medicare and Medicaid Services (CMS) has rejected Theranos’ plan of correction and considers sanctions, we have carefully considered our relationship with Theranos and believe it is in our customers’ best interests to terminate our partnership,” Brad Fluegel, Walgreens senior vice president and chief health care commercial market development officer, said in the statement.                    

Theranos rose to prominence with the claim that it could perform routine blood tests using just a few drops of blood from finger prick. Following the The Wall Street Journal’s October 2015 article, a number of the company’s other claims have been challenged—including, for example, that it worked with pharmaceutical company GlaxoSmithKline, according to The Verge.

A Theranos memo obtained by journalists in April noted that the Securities and Exchange Commission and the US Attorney’s Office were investigating whether the company may have misled investors.

The CMS launched an investigation of a Theranos laboratory in Newark, California, last fall, finding problems. The agency is expected to decide on possible sanctions against the company within the next two weeks, according to the Wall Street Journal

Hat tip: The Guardian

Update (June 13): “Quality and safety are our top priorities and we are working closely with government officials to ensure that we not only comply with all federal regulations but exceed them,” Brooke Buchanan, Theranos’s vice president of communications, said in a statement emailed to The Scientist.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!